Skip Navigation


Rheumatology Advance Access originally published online on October 24, 2006
Rheumatology 2006 45(12):1505-1513; doi:10.1093/rheumatology/kel358
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
45/12/1505    most recent
kel358v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Strand, V.
Right arrow Articles by Agarwal, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strand, V.
Right arrow Articles by Agarwal, S.
Related Collections
Right arrow Rehabilitation
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years

V. Strand, A. Balbir-Gurman1, K. Pavelka2, P. Emery3, N. Li4, M. Yin4, P. B. Lehane5 and S. Agarwal4

Division of Immunology, Stanford University, Palo Alto, CA, USA, 1B. Shine Department of Rheumatology, Rambam Medical Center, Haifa, Israel, 2Institute of Rheumatology, Prague University, Prague, Czech Republic, 3Department of Rheumatology, University of Leeds, Leeds, UK, 4Biostatistics and Clinical Science, Genentech, Inc., South San Francisco, CA, USA and 5Clinical Science, Roche Products Ltd, Welwyn Garden City, UK.

Correspondence to: Dr V. Strand, 306 Ramona Road, Portola Valley, CA 94028, USA. E-mail: vstrand{at}aol.com


  Abstract

Objectives. To evaluate the long-term impact on physical function of a single course of rituximab in rheumatoid factor, seropositive patients with active rheumatoid arthritis (RA) despite ongoing methotrexate treatment.

Methods. A randomized, controlled trial comparing rituximab alone [1000 mg intravenously (iv) on days 1 and 15, n= 40], or in combination with cyclophosphamide (750 mg iv on days 3 and 7, n= 41) or oral methotrexate (≥10 mg/week, n= 40) with placebo+ methotrexate (≥10 mg/week, n= 40), resulted in significant reductions in disease activity at weeks 24 and 48. Sustained improvements in physical function and standard effect sizes (SES) for changes in components of ACR and EULAR criteria were evaluated over 2 yrs.

Results. More patients receiving rituximab+ methotrexate completed a 2-yr follow-up without further treatment than those receiving placebo+ methotrexate (45% vs 15%, respectively), rituximab alone (10%) or rituximab+ cyclophosphamide (22%). This reflected a higher percentage of patients receiving rituximab+ methotrexate reporting improvements in Health Assessment Questionnaire Disability Index≥ minimum clinically important difference at 1 and 2 yrs (68% and 30%, respectively) compared with placebo+ methotrexate (28% and 15%), rituximab monotherapy (43% and 10%) or rituximab+ cyclophosphamide (39% and 12%). SES were high in all rituximab groups and revealed differing patterns of response over time.

Conclusion. A single course of rituximab with continuing methotrexate in patients with active RA provided clinically meaningful improvements in physical function over 2 yrs, with lower discontinuation rates and larger SES for improvements in ACR and EULAR criteria components.

KEY WORDS: Rituximab, Rheumatoid arthritis, Physical function, Methotrexate, Cyclophosphamide, HAQ-DI, ACR, EULAR


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
E. R. Soriano, C. Galarza-Maldonado, M. H. Cardiel, B. A. Pons-Estel, L. Massardo, C. V. Caballero-Uribe, A. F. Achurra-Castillo, L. A. Barile-Fabris, J. Chavez-Corrales, J. F. Diaz-Coto, et al.
Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context
Rheumatology, July 1, 2008; 47(7): 1097 - 1099.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.